EMD Millipore, the life science division of Merck KGaA has formed an upstream process development services with Precision Biologics, Inc., a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody. The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering, including colorectal, lung, ovarian, and pancreatic cancers.

Under the agreement, EMD Millipore will provide process development through its Provantage Services offering. The process development will occur at EMD Millipore's single-use GMP biodevelopment center in Martillac, France.

Source: EMD Millipore.